EVALUATION OF THE ACTIVITY OF PERIPHERAL BLOOD NATURAL KILLER CELLS IN HEALTHY SUBJECTS AND BREAST CANCER PATIENTS

Dieu Thi Thuy Chuyen1,2, Phung The Hai2, Nguyen Hoang Phuong2, Hoang Trung Kien2, Nguyen Ngoc Tuan2, Nguyen Dang Dung2, Do Khac Dai2,
1 Department of Biochemistry and Immunology, Vietnam National Cancer Hospital
2 Department of Immunology, Vietnam Military Medical University

Nội dung chính của bài viết

Tóm tắt

Objectives: To study Natural Killer (NK) cell activity (NK-IFNg) and some indicators related to immunological characteristics of peripheral blood NK cells in healthy people and breast cancer patients. Methods: We evaluated NK cell activity through its secretory characteristics (NK-IFNg) using ATGen's commercial NK VUE TestÒ (ATGen kit) on 35 healthy subjects (medical staff) and 132 cancer patients treated at Vietnam National Cancer Hospital  from August 2020 to February 2023. At the same time, we collected peripheral blood samples to conduct immunological characterization of peripheral blood NK cells based on the flow cytometer system (number, expression of the activation and inhibitory receptors such as NKG2A, NKG2D), and some other biomarkers (CEA, CA 15.3). Results: The secretory activity of peripheral blood NK cells (NKA-IFNγ) in breast cancer patients (1,013.46 ± 1,115.87 pg/mL) was statistically significantly lower than that in the healthy group ( 2,571.38 ± 827.52 pg/mL) ( ± SD) (p < 0.001). The proportion of breast cancer patients with NKA-IFNγ activity of a very low level (≤ 200 pg/mL) was 40.9% and that of the healthy subjects was 0%. There was no relationship between NKA-IFNγ and peripheral blood NK cell count, and the expression levels of the activating receptor NKG2D and the inhibitory receptor NKG2A. Patients with CEA and CA 15.3 serum levels above the normal limits accounted for relatively low percentages (10.6% and 6.1%). Conclusion: Breast cancer patients with very low NK cell activity accounted for a significant proportion (40.9%). NKA-IFNγ activity could be used as a potential tool for monitoring the immune system health status of breast cancer patients before and after receiving treatment interventions.

Chi tiết bài viết

Tài liệu tham khảo

1. Tran Van T., et al. Medical treatment of breast cancer. Medical Publishing House. 2019:5.
2. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-49. doi:10.1126/science.1198687.
3. Rocca YS, Roberti MP, Juliá EP, et al. Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by Cetuximab plus IL-2 or IL-15. Front Immunol. 2016; 7:413. doi:10.3389/fimmu.2016.00413.
4. Lee S byul, Cha J, Kim I kyung, et al. A high-throughput assay of NK cell activity in whole blood and its clinical application. Biochem Biophys Res Commun. 2014; 445(3):584-590. doi:10.1016/j.bbrc.2014.02.040.
5. Koo KC, Shim DH, Yang CM, et al. Reduction of the CD16-CD56 bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS ONE. 2013; 8(11). doi:10.1371/journal.pone.0078049.
6. Borg M, Wen SWC, Hansen TF, et al. Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients. J Int Med Res. 2022; 50(6):03000605221108924. doi:10.1177/03000605221108924.
7. Phan MT, Chun S, Kim SH, et al. Natural killer cell subsets and receptor expression in peripheral blood mononuclear cells of a healthy Korean population: Reference range, influence of age and sex, and correlation between NK cell receptors and cytotoxicity. Hum Immunol. 2017; 78(2):103-112. doi:10.1016/j.humimm.2016.11.006.
8. Barkin J, Rodriguez-Suarez R, Betito K. Association between natural killer cell activity and prostate cancer: a pilot study. Can J Urol. 2017; 24(2):8708-8713.
9. Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: A prospective longitudinal study. Clin Cancer Res Off J Am Assoc Cancer Res. 2001; 7(8):2357-2362.
10. Wang Y, Li W, Huang G, Zhu Y, Tao Q, Lv P. Clinical detection of peripheral blood natural killer cell activity. J Biosci Med. 2021; 9(5):28-36. doi:10.4236/jbm.2021.95004.